Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 4
1983 3
1984 4
1985 7
1986 11
1987 9
1988 18
1989 13
1990 17
1991 16
1992 14
1993 16
1994 14
1995 15
1996 23
1997 24
1998 18
1999 31
2000 18
2001 11
2002 7
2003 10
2004 9
2005 19
2006 11
2007 6
2008 5
2009 8
2010 9
2011 3
2012 10
2013 6
2014 3
2015 6
2016 4
2017 2
2018 2
2020 2
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 9935077

406 results

Results by year

Filters applied: . Clear all
Page 1
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P. Kraeber-Bodéré F, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3183s-3189s. Clin Cancer Res. 1999. PMID: 10541362
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F. Kraeber-Bodéré F, et al. J Nucl Med. 2010 Apr;51(4):624-31. doi: 10.2967/jnumed.109.070714. J Nucl Med. 2010. PMID: 20351352 Free article.
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, Ferreira TC, Bardiès M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF. Kraeber-Bodéré F, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3190s-3198s. Clin Cancer Res. 1999. PMID: 10541363 Clinical Trial.
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF. Vuillez JP, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3259s-3267s. Clin Cancer Res. 1999. PMID: 10541373 Clinical Trial.
406 results